American Journal of Epidemiology Advance Access originally published online on March 3, 2007
American Journal of Epidemiology 2007 165(10):1187-1198; doi:10.1093/aje/kwm006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk
1 Department of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, NC
2 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
3 New York City Department of Health and Mental Hygiene, New York, NY
4 Department of Community Medicine, Mt. Sinai School of Medicine, New York, NY
5 Department of Community and Family Medicine, Duke University Medical Center, Durham, NC
6 Sticht Center on Aging, Wake Forest University School of Medicine, Winston-Salem, NC
7 Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY
Correspondence to Dr. Sumitra Shantakumar, Worldwide Epidemiology, GlaxoSmithKline Research and Development, P.O. Box 13398, Five Moore Drive, Research Triangle Park, NC 27709-3398 (e-mail: sumitra.y.shantakumar{at}gsk.com).
Received for publication February 8, 2006. Accepted for publication November 1, 2006.
It is unclear whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively. The authors utilized data from 1,478 cases and 1,493 controls aged 20–98 years with known menopausal status, who had participated in a population-based, case-control study conducted on Long Island during 1996–1997. Exogenous hormone use over the lifecourse was assessed by use of memory aids. The authors examined associations among women in these subgroups: premenopausal (n = 968), postmenopausal <65 years (n = 1,045), and postmenopausal 
65 years (n = 958). Among premenopausal women, risk was increased for ever use of HBC (odds ratio (OR) = 1.37, 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49). There was no effect of ever HBC use among postmenopausal women aged less than 65 years, but risk was modestly elevated for more than 5 years of HRT use (OR = 1.41, 95% CI: 1.00, 1.99). Among postmenopausal women aged 65 years or more, odds ratios for HBC or HRT use were around the null. These results emphasize that timing of exogenous hormone use is important. Women who used these hormones before menopause had elevated risks, but the harmful effects began to decline with age after menopause.
aged; breast neoplasms; contraceptives, oral; hormone replacement therapy; perimenopause; postmenopause; premenopause; progestins
Abbreviations: CI, confidence interval; HBC, hormonal birth control; HRT, hormone replacement therapy; LIBCSP, Long Island Breast Cancer Study Project; OR, odds ratio
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Chen, M. D. Gammon, S. L. Teitelbaum, J. A. Britton, M. B. Terry, S. Shantakumar, S. M. Eng, Q. Wang, I. Gurvich, A. I. Neugut, et al. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project Carcinogenesis, April 1, 2008; 29(4): 766 - 771. [Abstract] [Full Text] [PDF]
|
|